Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum

Per Ljungman(Leiden University Medical Center), Dana G. Wolf(Hebrew University of Jerusalem), Yoichiro Natori(University of Miami), Raymund R. Razonable(Wayne State University), Atul Humar, Paul Griffiths(University College London), Monica A. Slavin(Peter MacCallum Cancer Centre), Aimee Hodowanec(United States Food and Drug Administration), Cyrus Badshah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Oriol Manuel(University of Lausanne), Veronica Miller(University of California, Berkeley), Angie Caliendo, Martha Fournier(Takeda (United States)), David Navarro(Universitat de València), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Michael Boeckh(University of Washington), Andreas Pikis(Children's National), Michelle Wong, Sophie Alain(Université de Limoges), Parmjeet Randhawa(University of Pittsburgh Medical Center), Gabriel Westman(Uppsala University), Sunwen Chou, Fareed Khawaya(The University of Texas MD Anderson Cancer Center), Andreas Piki, Takashi Komatsu(United States Food and Drug Administration), Camille N. Kotton(Harvard University), Ajit P. Limaye(University of Washington), Robin K. Avery(Johns Hopkins University)
Clinical Infectious Diseases
July 23, 2024
Cited by 145


Related Papers